Merck reported a bigger-than-expected third-quarter profit on Thursday, driven by higher demand for its blockbuster cancer immunotherapy Keytruda, and the U.S. drugmaker announced a $10 billion share buyback.
from Earnings https://ift.tt/2RhumNH
via IFTTT
No comments:
Post a Comment